Ngamcherdtrakul et al., 2021 - Google Patents
In situ tumor vaccination with nanoparticle co‐delivering CpG and STAT3 siRNA to effectively induce whole‐body antitumor immune responseNgamcherdtrakul et al., 2021
View PDF- Document ID
- 3004144280429715794
- Author
- Ngamcherdtrakul W
- Reda M
- Nelson M
- Wang R
- Zaidan H
- Bejan D
- Hoang N
- Lane R
- Luoh S
- Leachman S
- Mills G
- Gray J
- Lund A
- Yantasee W
- Publication year
- Publication venue
- Advanced Materials
External Links
Snippet
The success of immunotherapy with immune checkpoint inhibitors (ICIs) in a subset of individuals has been very exciting. However, in many cancers, responses to current ICIs are modest and are seen only in a small subsets of patients. Herein, a widely applicable …
- 206010028980 Neoplasm 0 title abstract description 172
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ngamcherdtrakul et al. | In situ tumor vaccination with nanoparticle co‐delivering CpG and STAT3 siRNA to effectively induce whole‐body antitumor immune response | |
| Musetti et al. | Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy | |
| Sun et al. | Nanomedicine and macroscale materials in immuno-oncology | |
| Garland et al. | Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy | |
| Melero et al. | Intratumoural administration and tumour tissue targeting of cancer immunotherapies | |
| Escriche‐Navarro et al. | Mesoporous silica materials as an emerging tool for cancer immunotherapy | |
| Phuengkham et al. | A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy | |
| Hager et al. | Nucleic acid-based approaches for tumor therapy | |
| Wang et al. | Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma | |
| Zhou et al. | Towards curative cancer immunotherapy: overcoming posttherapy tumor escape | |
| Bo et al. | Biomaterial‐based in situ cancer vaccines | |
| Ilett et al. | Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus | |
| Cheng et al. | Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect | |
| Han et al. | Combination of Metal‐Phenolic Network‐Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy | |
| Liu et al. | Leveraging macrophages for cancer theranostics | |
| Fujii et al. | Cycloamylose‐nanogel drug delivery system‐mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment | |
| Ngamcherdtrakul et al. | Targeted nanoparticle for co‐delivery of HER2 siRNA and a taxane to mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis | |
| Zhang et al. | Modified Fe 3 O 4 magnetic nanoparticle delivery of CpG inhibits tumor growth and spontaneous pulmonary metastases to enhance immunotherapy | |
| Ruiz-de-Angulo et al. | Chemically programmed vaccines: iron catalysis in nanoparticles enhances combination immunotherapy and immunotherapy-promoted tumor ferroptosis | |
| Mei et al. | Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy | |
| Liu et al. | In situ therapeutic cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2 | |
| Zhao et al. | HSP70-promoter-driven CRISPR/Cas9 system activated by reactive oxygen species for multifaceted anticancer immune response and potentiated immunotherapy | |
| JP2022549270A (en) | Biomaterial-based non-antigen vaccine and its use | |
| Gong et al. | Enhancing in situ cancer vaccines using delivery technologies | |
| KR20220144831A (en) | Compositions and methods for organ protective expression and modulation of encoding ribonucleic acids |